NASDAQ:ANIK Anika Therapeutics (ANIK) Stock Price, News & Analysis $16.55 +0.32 (+1.97%) (As of 10:58 AM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Anika Therapeutics Stock (NASDAQ:ANIK) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Anika Therapeutics alerts:Sign Up Key Stats Today's Range$16.25▼$16.6750-Day Range$16.04▼$25.2152-Week Range$15.82▼$29.11Volume21,217 shsAverage Volume72,310 shsMarket Capitalization$242.39 millionP/E RatioN/ADividend YieldN/APrice Target$24.50Consensus RatingModerate Buy Company OverviewAnika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief. The company's joint preservation and restoration product family comprises and orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and Hyalomatrix used for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.Read More… Anika Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks74th Percentile Overall ScoreANIK MarketRank™: Anika Therapeutics scored higher than 74% of companies evaluated by MarketBeat, and ranked 398th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingAnika Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageAnika Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Anika Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Anika Therapeutics are expected to grow in the coming year, from ($0.84) to ($0.41) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Anika Therapeutics is -2.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Anika Therapeutics is -2.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAnika Therapeutics has a P/B Ratio of 1.12. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.60% of the float of Anika Therapeutics has been sold short.Short Interest Ratio / Days to CoverAnika Therapeutics has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Anika Therapeutics has recently decreased by 27.79%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAnika Therapeutics does not currently pay a dividend.Dividend GrowthAnika Therapeutics does not have a long track record of dividend growth. Sustainability and ESG3.6 / 5Environmental Score-2.05 Percentage of Shares Shorted2.60% of the float of Anika Therapeutics has been sold short.Short Interest Ratio / Days to CoverAnika Therapeutics has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Anika Therapeutics has recently decreased by 27.79%, indicating that investor sentiment is improving significantly. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Anika Therapeutics this week, compared to 2 articles on an average week. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Anika Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.86% of the stock of Anika Therapeutics is held by insiders.Percentage Held by Institutions91.53% of the stock of Anika Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Anika Therapeutics' insider trading history. Receive ANIK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Anika Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ANIK Stock News HeadlinesAnika To Participate in 43rd Annual J.P. Morgan Healthcare ConferenceDecember 23 at 4:01 PM | globenewswire.comAnika To Participate in December 2024 Investor ConferencesNovember 22, 2024 | globenewswire.comA.I. Trading System Helps Some Traders Pocket $1,100 per DAY!What if I told you 60 seconds a day could completely change your life? This AI-powered trading system finds high-probability option trades in less than 60 seconds a dayDecember 24, 2024 | Prosper Trading Academy (Ad)Anika Therapeutics Navigates Geopolitical Risks Amid Global ConflictsNovember 7, 2024 | markets.businessinsider.comAnika Therapeutics, Inc. (NASDAQ:ANIK) Q3 2024 Earnings Call TranscriptNovember 4, 2024 | msn.comAnika Therapeutics price target lowered to $25 from $37 at BarringtonNovember 3, 2024 | markets.businessinsider.comAnika (ANIK) Earnings Dates & ReportsNovember 3, 2024 | investing.comAnika Therapeutics, Inc. (ANIK) Q3 2024 Earnings Call TranscriptNovember 2, 2024 | seekingalpha.comSee More Headlines ANIK Stock Analysis - Frequently Asked Questions How have ANIK shares performed this year? Anika Therapeutics' stock was trading at $22.66 at the start of the year. Since then, ANIK stock has decreased by 28.4% and is now trading at $16.23. View the best growth stocks for 2024 here. How were Anika Therapeutics' earnings last quarter? Anika Therapeutics, Inc. (NASDAQ:ANIK) announced its quarterly earnings data on Thursday, August, 8th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.23 by $0.24. The biotechnology company had revenue of $41.92 million for the quarter, compared to analyst estimates of $39.90 million. Anika Therapeutics had a negative trailing twelve-month return on equity of 2.22% and a negative net margin of 59.40%. Who are Anika Therapeutics' major shareholders? Top institutional investors of Anika Therapeutics include Caligan Partners LP (9.80%), Geode Capital Management LLC (2.22%), State Street Corp (2.08%) and Capital Management Corp VA (1.99%). Insiders that own company stock include David Colleran, Cheryl R Blanchard, Jeffery S Thompson and Michael L Levitz. View institutional ownership trends. How do I buy shares of Anika Therapeutics? Shares of ANIK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Anika Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Anika Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Advanced Micro Devices (AMD), ServiceNow (NOW) and Arista Networks (ANET). Company Calendar Last Earnings8/08/2024Today12/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryHealth Care Supplies Current SymbolNASDAQ:ANIK CUSIP03525510 CIK898437 Webwww.anikatherapeutics.com Phone(781) 457-9000Fax781-305-9720Employees357Year Founded1992Price Target and Rating Average Stock Price Target$24.50 High Stock Price Target$25.00 Low Stock Price Target$24.00 Potential Upside/Downside+51.0%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($6.65) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-82,670,000.00 Net Margins-59.40% Pretax Margin-57.58% Return on Equity-2.22% Return on Assets-1.75% Debt Debt-to-Equity RatioN/A Current Ratio5.34 Quick Ratio3.78 Sales & Book Value Annual Sales$164.17 million Price / Sales1.45 Cash Flow$4.47 per share Price / Cash Flow3.63 Book Value$14.50 per share Price / Book1.12Miscellaneous Outstanding Shares14,646,000Free Float13,495,000Market Cap$237.70 million OptionableOptionable Beta0.89 Social Links The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:ANIK) was last updated on 12/24/2024 by MarketBeat.com Staff From Our Partners"This looks and feels like 2000," says investing legendOur senior analyst Dan Ferris says a new surprise crisis could begin at any moment... and this time, he says i...Stansberry Research | SponsoredA.I. Trading System Helps Some Traders Pocket $1,100 per DAY!What if I told you 60 seconds a day could completely change your life? This AI-powered trading syst...Prosper Trading Academy | SponsoredTiny Mineral, Massive Market OpportunityImagine a mineral so small it fits in the palm of your hand... yet its potential could transform the world's f...i2i Marketing Group, LLC | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anika Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anika Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.